RxDoctor Payments Data

Olawale Osunsanya, MD

Nephrology · Dothan, ALNPI 1013998491

Payments from drug & device makers

$1,611in general payments, 2019–2025

Across 63 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$328
  • Fresenius USA Marketing, Inc.$223
  • Bard Peripheral Vascular, Inc.$133
  • Medtronic$123
  • Amgen$121
  • Bayer$117
  • plus $565 from 12 others

What the payments were for

  • Food & beverage$1,55597%
  • Education$563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,611 in reported general payments places this provider in the 40th percentile of 164 nephrology providers in Alabama.

See all nephrology providers in Alabama

Medicare billing

Part B allowed, 2024
$213,354
Medicare patients
415
Services billed
1,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol165$159,154
JardianceEmpagliflozin66$56,592
VelphoroSucroferric Oxyhydroxide17$51,199
VeltassaPatiromer Calcium Sorbitex18$22,382
EliquisApixaban26$18,498
AuryxiaFerric Citrate15$18,344
Sevelamer Carbonate61$13,461
LinzessLinaclotide20$10,365
LokelmaSodium Zirconium Cyclosilicate18$9,765
Clonidine67$6,605
Calcium Acetate52$4,151
Bumetanide83$2,364
Losartan Potassium268$1,261
Lidocaine-PrilocaineLidocaine/Prilocaine62$1,242
Hydralazine Hcl103$1,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$328$168,919183 claims
Boehringer IngelheimJardiance$98$56,59266 claims
Fresenius USA Marketing, Inc.Velphoro$223$51,19917 claims
Akebia Therapeutics IncAuryxia$76$18,34415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 164 nephrology providers in Alabama.

Other nephrology in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →